Study study type PathologyT1T0Patientssample sizesROB Results

breast cancer - adjuvant breast cancer - adjuvant

versus trastuzumab
trastuzumab emtansine
KATHERINE, 2019
  NCT01772472
RCTes-BC - HER2 positive - (neo)adjuvant (NA)trastuzumab emtasine (T-DM1)trastuzumabPatients had histologically confirmed, HER2-positive, nonmetastatic, invasive primary breast cancer and if residual invasive disease after completion of taxane-based neoadjuvant chemotherapy ad and had to have completed at least six cycles (16 weeks) of a conventional preoperative chemotherapy regimen containing a minimum of 9 weeks of taxane-based therapy and 9 weeks of trastuzumab therapy.743 / 743high
conclusif
  • inconclusive 30 % decrease in deaths (OS) (PE)
  • demonstrated 50 % decrease in iDFS (PE)